- Considering innovative and flexible trial designs to maximise data from small populations and allow for protocol flexibility
- Realistically assessing inclusion and exclusion criteria to ensure adequate enrolment
- Minimizing patient burden throughout
- Engaging early with patient advocacy groups and regulatory agencies for protocol feedback
- Collaborating with rare disease CROs to employ statistical methods, help select appropriate endpoints and enhance trial’s chance of success
